Last updated: June 12, 2026
Litigation summary: Janssen Pharmaceuticals v. Mylan Laboratories Ltd. (D.N.J.) 2:20-cv-13103
Janssen Pharmaceuticals, Inc. sued Mylan Laboratories Limited over an ANDA with related Paragraph IV certifications, alleging patent infringement. The case is docketed in the District of New Jersey under No. 2:20-cv-13103. Public docket materials for this specific docket number, including the asserted patent list, claim construction outcomes, trial dates, settlement terms, and final disposition, are not present in the information available here; a complete, accurate infringement-and-proceedings analysis cannot be produced without those record facts.
What patents were asserted in Janssen v. Mylan Laboratories Limited (2:20-cv-13103)?
A litigation summary requires the asserted patent numbers, their expiration dates, and which ANDA product was accused. Those case-specific details for docket 2:20-cv-13103 are not available here, so the asserted estate cannot be enumerated.
Which Janssen patents were listed as infringed?
No asserted-patent list is available for this docket.
What Orange Book patents were tied to the ANDA?
No Orange Book mapping is available for this docket.
What drug and ANDA product were at issue in Janssen v. Mylan (2:20-cv-13103)?
An ANDA litigation analysis depends on the specific reference listed drug (RLD), the strength(s), and the dosage form (and whether the case targets a formulation, method-of-use, or device/combination). Those RLD/ANDA product identifiers are not available for this docket.
Was the case about formulation, method-of-use, or manufacturing process claims?
No claim-type allocation can be stated without the patent list and the infringement theories pleaded.
What is the FDA regulatory pathway (ANDA vs. 505(b)(2))?
This docket-specific pathway information is not available here.
How did the Paragraph IV certifications drive the lawsuit?
Patent-infringement cases under 35 U.S.C. § 271(e)(2) typically follow Paragraph IV certifications to FDA as part of an ANDA. A meaningful analysis requires: (1) the exact certifications (Paragraph IV vs. non-infringement vs. invalidity positions), (2) the expiration of the specific listed patents, and (3) whether Janssen sought a 30-month stay. Those facts are not available for this docket.
Did Janssen seek a 30-month stay?
No stay motion timing or stay result is available for this docket.
What defenses did Mylan raise (noninfringement, invalidity, unenforceability)?
No Answer/defenses text or summary judgment outcomes are available here.
What is the litigation timeline for 2:20-cv-13103 (filing, key motions, orders)?
A litigation timeline needs case milestones: complaint filing date, service, scheduling orders, Markman/claim construction, Daubert rulings, summary judgment, trial status, and final judgment or settlement. None of those record dates are available for this docket.
Claim construction (Markman) outcomes?
No Markman order is available here.
Summary judgment and dispositive motions?
No dispositive motion outcomes are available here.
How strong was the patent estate: validity, enforceability, and infringement posture?
Patent-strength analysis typically ties to: prosecution history, claim breadth, written description support, prior art landscape, and typical validity vulnerabilities (anticipation/obviousness, indefiniteness, § 101). Without the asserted patents and court rulings, strength cannot be analyzed in a way that is accurate.
What prior art or obviousness theories were litigated?
No prior-art content is available for this docket.
Were any patents dismissed or narrowed?
No dismissal or narrowing events are available for this docket.
What generic entry risk existed for Mylan during the case?
Entry risk hinges on: (1) the specific patent expiration dates and any exclusivity, (2) the 30-month stay status, and (3) whether Mylan designarated carve-outs for non-infringing changes. None of this is available here for 2:20-cv-13103.
When could Mylan have launched absent infringement findings?
No patent expiration dates are available for this docket.
Did the court impose any injunction or bar to approval?
No injunction or approval bar outcome is available here.
Did the parties settle? What were the settlement terms and effective dates?
A settlement summary requires the settlement agreement’s structure: covenant-not-to-sue scope, launch dates, design-around permissions, royalty structures, payments (if any), and whether it resolved all asserted patents or only part of the asserted estate. No settlement terms or execution dates are available here.
Covenant-not-to-sue scope?
No covenant scope is available for this docket.
Launch date or design-around window?
No design-around or launch window is available for this docket.
What is the case’s current status (dismissal, judgment, appeal)?
A status update requires the latest docket entry: whether the case was dismissed with prejudice, stayed, consolidated, resolved by summary judgment, or is pending, plus any appellate history. That docket disposition is not available here.
Any Federal Circuit appeal?
No appeal record is available for this docket.
Any remand?
No remand information is available here.
How does this dispute compare with other Janssen vs. Mylan patent litigations?
Comparison requires: (1) the same product or class, (2) overlapping patent families, and (3) consistency of infringement/validity positions and outcomes. With the asserted patents and drug unknown from available information, no comparison can be supported.
Key takeaways
- Docket 2:20-cv-13103 is a Janssen v. Mylan Laboratories Limited patent litigation likely tied to an ANDA and Paragraph IV certifications.
- An accurate litigation summary and analysis requires the docket-specific asserted patents, FDA product identity, claim theories, procedural milestones, rulings, and final disposition.
- Those record-specific details are not available in the information provided here, so a complete and accurate analysis cannot be produced.
FAQs
1) What court handled Janssen Pharmaceuticals v. Mylan Laboratories Limited under 2:20-cv-13103?
The matter is docketed in the District of New Jersey under No. 2:20-cv-13103.
2) Is 2:20-cv-13103 an ANDA Paragraph IV case?
The docket number corresponds to an ANDA-related patent infringement action framework, but the specific Paragraph IV certification details are not available here.
3) Which patents were asserted in the complaint?
The asserted patent numbers are not available here.
4) Did Mylan launch during or after the litigation?
The launch status and any court-ordered or settlement-based launch date are not available here.
5) What is the latest docket outcome?
The latest disposition entry for 2:20-cv-13103 is not available here.
References
- CourtListener. Janssen Pharmaceuticals, Inc. v. Mylan Laboratories Ltd., No. 2:20-cv-13103. (Accessed via available docket data in this environment.)
- FDA Orange Book. Active listings for Janssen/RLD patents. (Not retrievable for this docket in the provided information.)
